Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S065 - Atopic Dermatitis

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the high burden of atopic dermatitis
  • Identify barrier and immune defects in atopic dermatitis that form the basis for new therapies
  • Use improved understanding of available and emergent therapies in making decisions on atopic dermatitis management

Description

This session provides an up-to-date overview about atopic dermatitis, new discoveries and new therapies. The session is directed towards dermatologists and other health care providers who treat adults and/or children with atopic dermatitis. Among topics to be reviewed are: i) The Burden of Atopic Dermatitis (Dr. Jonathan Silverberg); ii) AD Pathogenesis - the Epidermal Barrier (Dr. Amy Paller) and the Immune System (Dr. Emma Guttman-Yassky); iii) Skin Bacterio-therapy - the Potential to Cure Atopic Dermatitis with the Microbiome (Dr. Richard Gallo); iv) Topical Therapy (Dr. Lawrence Eichenfield) and v) Systemic therapy (Dr. Eric Simpson).

Disclosures

  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Gallo, Richard L., MD, PhD: Allergan, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Hoffman-La Roche Ltd. – C(H); Johnson and Johnson – A(H); MatriSys Bioscience – F(SO); Sente Labs – C(Fees);
  • Guttman, Emma, MD, PhD: AbbVie – C(H); Allergan, Inc. – C(H); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana Biosciences, LLC – C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Dermira – A(H), C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Galderma Research & Development, LLC – A(H), C(H); Glenmark Generics Inc. – B(H), C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding); Medimmune – A(H), C(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); sanofi-aventis – C(H); Sanofi/Regeneron – B(H); Stiefel a GSK company – C(H); Theravance Biopharma – C(H); Vitae Pharmaceuticals – C(H), I(Grants/Research Funding);
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); BridgeBio Pharma, LLC – A(H), C(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H), C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Silverberg, Jonathan I., MD, PhD, MPH: AbbVie – C(H), I(NC); AnaptysBio – C(H); Asana Biosciences, LLC – C(H); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Glenmark Generics Inc. – C(H); Kiniksa Pharmaceuticals, Ltd. – C(H), I(NC); Leo Pharma Inc – A(H); Leo Pharma Inc. – I(H); Medimmune – C(H); Menlo Therapeutics – A(H), I(NC); Pfizer Inc. – A(H), C(H); PuriCore, Inc. – C(H); Regeneron – C(H), I(NC), SP(H); Sanofi – C(Grants/Research Funding);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees); Demira – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Leo Pharma Inc. – C(Fees); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding);
Schedule
Monday, February 19
1:00 PM
Dr. Paller / Introduction
1:05 PM
Dr. Silverberg / The Burden of Atopic Dermatitis: from Population to Bedside
1:35 PM
Dr. Paller / Pathogenesis - the Epidermal Barrier and its Role
2:00 PM
Dr. Guttman / Pathogenesis – the Immune System and Relevance to Targeted Therapeutics
2:30 PM
Dr. Simpson / Systemic therapy - What’s Here?/ What’s Emerging?
3:05 PM
Dr. Eichenfield / Topical Therapy
3:35 PM
Dr. Gallo / Skin Bacterio-therapy - A Scientist’s Dream to Cure Atopic Dermatitis with the Microbiome
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 6D
  • CME Credits
    3.00
  • Type
    New
Directors/Co-Directors
  • Amy S. Paller, MD, FAAD
Speakers
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Eric Lawrence Simpson, MD, FAAD
  • Jonathan I. Silverberg, MD, PhD, MPH, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
  • Richard L. Gallo, MD, PhD, FAAD